Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 19 |
| List of Tables | 17 | 3 |
| List of Figures | 20 | 1 |
| Introduction | 21 | 1 |
| Global Markets Direct Report Coverage | 21 | 1 |
| Atopic Dermatitis Overview | 22 | 1 |
| Therapeutics Development | 23 | 2 |
| Pipeline Products for Atopic Dermatitis Overview | 23 | 1 |
| Pipeline Products for Atopic Dermatitis Comparative Analysis | 24 | 1 |
| Atopic Dermatitis Therapeutics under Development by Companies | 25 | 6 |
| Atopic Dermatitis Therapeutics under Investigation by Universities/Institutes | 31 | 1 |
| Atopic Dermatitis Pipeline Products Glance | 32 | 4 |
| Late Stage Products | 32 | 1 |
| Clinical Stage Products | 33 | 1 |
| Early Stage Products | 34 | 1 |
| Unknown Stage Products | 35 | 1 |
| Atopic Dermatitis Products under Development by Companies | 36 | 8 |
| Atopic Dermatitis Products under Investigation by Universities/Institutes | 44 | 1 |
| Atopic Dermatitis Companies Involved in Therapeutics Development | 45 | 77 |
| AbbVie Inc | 45 | 1 |
| Accolade Pharmaceuticals, LLC | 46 | 1 |
| AlbireoPharma | 47 | 1 |
| Almirall, S.A. | 48 | 1 |
| Amgen Inc. | 49 | 1 |
| Amorepacific Corporation | 50 | 1 |
| Anacor Pharmaceuticals, Inc. | 51 | 1 |
| AnaMar AB | 52 | 1 |
| AnaptysBio, Inc. | 53 | 1 |
| AnGes MG, Inc. | 54 | 1 |
| arGEN-X BV | 55 | 1 |
| Avexxin AS | 56 | 1 |
| Blueberry Therapeutics Ltd | 57 | 1 |
| Brickell Biotech, Inc. | 58 | 1 |
| Celgene Corporation | 59 | 1 |
| Cell Medica Limited | 60 | 1 |
| Cellceutix Corporation | 61 | 1 |
| ChemoCentryx, Inc. | 62 | 1 |
| ChironWells GmbH | 63 | 1 |
| Chugai Pharmaceutical Co., Ltd. | 64 | 1 |
| Creabilis SA | 65 | 1 |
| Curapel Limited | 66 | 1 |
| Dermala Inc | 67 | 1 |
| Dr. August Wolff GmbH &Co. KG Arzneimittle | 68 | 1 |
| Eli Lilly and Company | 69 | 1 |
| F. Hoffmann-La Roche Ltd. | 70 | 1 |
| Foamix Pharmaceuticals Ltd. | 71 | 1 |
| Fountain Biopharma Inc. | 72 | 1 |
| Galapagos NV | 73 | 1 |
| GlaxoSmithKline Plc | 74 | 1 |
| Glenmark Pharmaceuticals Ltd. | 75 | 1 |
| Grupo Ferrer Internacional, S.A. | 76 | 1 |
| Han Wha Pharma Co., Ltd. | 77 | 1 |
| HanAll Biopharma Co., Ltd. | 78 | 1 |
| Heptares Therapeutics Limited | 79 | 1 |
| Herantis Pharma Plc | 80 | 1 |
| iCo Therapeutics Inc. | 81 | 1 |
| Immune Pharmaceuticals Inc. | 82 | 1 |
| Inflamalps SA | 83 | 1 |
| Japan Tobacco Inc. | 84 | 1 |
| Johnson &Johnson | 85 | 1 |
| Kang Stem Biotech Co., Ltd. | 86 | 1 |
| KPI Therapeutics, Inc. | 87 | 1 |
| LegoChem Biosciences, Inc | 88 | 1 |
| LEO Pharma A/S | 89 | 1 |
| Madam Therapeutics B.V. | 90 | 1 |
| MedImmune, LLC | 91 | 1 |
| NeoPharm Co., Ltd. | 92 | 1 |
| Nippon Shinyaku Co., Ltd. | 93 | 1 |
| Novan, Inc. | 94 | 1 |
| Novartis AG | 95 | 1 |
| Orbis Biosciences Inc | 96 | 1 |
| Otsuka Holdings Co., Ltd. | 97 | 1 |
| Oxagen Limited | 98 | 1 |
| Pfizer Inc. | 99 | 1 |
| Pharis Biotec GmbH | 100 | 1 |
| Pharmedartis GmbH | 101 | 1 |
| Provectus Biopharmaceuticals, Inc. | 102 | 1 |
| PuriCore Plc | 103 | 1 |
| Quorum Innovations LLC | 104 | 1 |
| Regeneron Pharmaceuticals Inc | 105 | 1 |
| Signum Dermalogix, Inc | 106 | 1 |
| Spherium Biomed S.L. | 107 | 1 |
| sterna biologicals Gmbh &Co KG | 108 | 1 |
| Sucampo Pharmaceuticals, Inc. | 109 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 110 | 1 |
| SWITCH Biotech LLC | 111 | 1 |
| Takeda Pharmaceutical Company Limited | 112 | 1 |
| Thesan Pharmaceuticals, Inc. | 113 | 1 |
| Tioga Pharmaceuticals, Inc. | 114 | 1 |
| Torrent Pharmaceuticals Limited | 115 | 1 |
| Valeant Pharmaceuticals International, Inc. | 116 | 1 |
| Vicore Pharma AB | 117 | 1 |
| Vitae Pharmaceuticals, Inc. | 118 | 1 |
| VivaCell Biotechnology Espana S.L. | 119 | 1 |
| Xencor, Inc. | 120 | 1 |
| Ziarco Pharma Ltd | 121 | 1 |
| Atopic Dermatitis Therapeutics Assessment | 122 | 15 |
| Assessment by Monotherapy Products | 122 | 1 |
| Assessment by Target | 123 | 5 |
| Assessment by Mechanism of Action | 128 | 5 |
| Assessment by Route of Administration | 133 | 2 |
| Assessment by Molecule Type | 135 | 2 |
| Drug Profiles | 137 | 215 |
| A-3914 Drug Profile | 137 | 1 |
| A-5425 Drug Profile | 138 | 1 |
| AKP-11 Drug Profile | 139 | 2 |
| Allergen for House Dust Mite Induced Atopic Dermatitis Drug Profile | 141 | 1 |
| ALX-101 Drug Profile | 142 | 1 |
| AM-1030 Drug Profile | 143 | 1 |
| AMG-0101 Drug Profile | 144 | 2 |
| Anatabine Drug Profile | 146 | 3 |
| ANB-020 Drug Profile | 149 | 2 |
| apremilast Drug Profile | 151 | 11 |
| Aptamers to Inhibit Galectin-3 for Atopic Dermatitis Drug Profile | 162 | 1 |
| ARGX-112 Drug Profile | 163 | 1 |
| ARN-077 Drug Profile | 164 | 1 |
| asimadoline Drug Profile | 165 | 2 |
| AVX-001 Drug Profile | 167 | 1 |
| B-244 Drug Profile | 168 | 1 |
| baricitinib Drug Profile | 169 | 7 |
| BB-2702 Drug Profile | 176 | 1 |
| BBI-2000 Drug Profile | 177 | 1 |
| BBI-5000 Drug Profile | 178 | 1 |
| bertilimumab Drug Profile | 179 | 4 |
| betamethasone valerate Drug Profile | 183 | 1 |
| Biologic for Atopic Dermatitis and Eczema Drug Profile | 184 | 1 |
| brilacidin tetrahydrochloride Drug Profile | 185 | 9 |
| BTX-1204 Drug Profile | 194 | 1 |
| C-21 Drug Profile | 195 | 2 |
| CBP-174 Drug Profile | 197 | 1 |
| CBP-201 Drug Profile | 198 | 1 |
| CCX-6239 Drug Profile | 199 | 1 |
| CDE-001 Drug Profile | 200 | 1 |
| Cis-Urocanic Acid Drug Profile | 201 | 3 |
| cobamamide Drug Profile | 204 | 1 |
| crisaborole Drug Profile | 205 | 5 |
| CT-101 Drug Profile | 210 | 1 |
| CT-103 Drug Profile | 211 | 1 |
| CT-327 Drug Profile | 212 | 3 |
| CT-340 Drug Profile | 215 | 1 |
| cyclosporine Drug Profile | 216 | 1 |
| dalazatide Drug Profile | 217 | 5 |
| DMT-210 Drug Profile | 222 | 1 |
| Drug for Atopic Dermatitis Drug Profile | 223 | 1 |
| dupilumab Drug Profile | 224 | 6 |
| FB-825 Drug Profile | 230 | 1 |
| fevipiprant Drug Profile | 231 | 2 |
| FIB-116 Drug Profile | 233 | 1 |
| Furestem-AD Drug Profile | 234 | 1 |
| GBR-830 Drug Profile | 235 | 1 |
| GLPG-2534 Drug Profile | 236 | 1 |
| GSK-3772847A Drug Profile | 237 | 1 |
| Histimex Drug Profile | 238 | 1 |
| HS-378 Drug Profile | 239 | 1 |
| IDP-124 Drug Profile | 240 | 1 |
| JTE-052 Drug Profile | 241 | 1 |
| KPI-150 Drug Profile | 242 | 1 |
| LCB-030110 Drug Profile | 243 | 1 |
| lebrikizumab Drug Profile | 244 | 3 |
| LEKTI-6 Drug Profile | 247 | 1 |
| LEO-32731 Drug Profile | 248 | 1 |
| LEO-39652 Drug Profile | 249 | 1 |
| MEDI-9314 Drug Profile | 250 | 1 |
| mepolizumab Drug Profile | 251 | 5 |
| MLR-1130 Drug Profile | 256 | 1 |
| mometasone furoate Drug Profile | 257 | 1 |
| Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation Drug Profile | 258 | 1 |
| Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis Drug Profile | 259 | 1 |
| Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer Drug Profile | 260 | 1 |
| N-oleoylethanolamine Drug Profile | 261 | 1 |
| nemolizumab Drug Profile | 262 | 1 |
| NPH-12 Drug Profile | 263 | 1 |
| NS-141 Drug Profile | 264 | 1 |
| OC-000459 Drug Profile | 265 | 2 |
| OC-2417 Drug Profile | 267 | 1 |
| octenidine hydrochloride Drug Profile | 268 | 1 |
| OLX-103 Drug Profile | 269 | 1 |
| omiganan pentahydrochloride Drug Profile | 270 | 2 |
| OPA-15406 Drug Profile | 272 | 2 |
| P-10 Drug Profile | 274 | 1 |
| P-148 Drug Profile | 275 | 1 |
| PAC-14028 Drug Profile | 276 | 2 |
| Peptide to Antagonize CX3CR1 for Atopic Dermatitis Drug Profile | 278 | 1 |
| Peptides to Antagonize TNFR-1 for Atopic Dermatitis Drug Profile | 279 | 1 |
| PF-04965842 Drug Profile | 280 | 1 |
| PH-10 Drug Profile | 281 | 3 |
| PL-601 Drug Profile | 284 | 1 |
| PMA-101R Drug Profile | 285 | 1 |
| PMA-201 Drug Profile | 286 | 1 |
| PMA-411R Drug Profile | 287 | 1 |
| PR-022 Drug Profile | 288 | 1 |
| prednisone Drug Profile | 289 | 1 |
| PZ-235 Drug Profile | 290 | 1 |
| Q-301 Drug Profile | 291 | 1 |
| Qi-507 Drug Profile | 292 | 1 |
| roflumilast Drug Profile | 293 | 5 |
| RTU-1096 Drug Profile | 298 | 2 |
| RVT-501 Drug Profile | 300 | 1 |
| SB-011 Drug Profile | 301 | 1 |
| SB-414 Drug Profile | 302 | 1 |
| secukinumab Drug Profile | 303 | 13 |
| SIG-1311 Drug Profile | 316 | 1 |
| SIG-1322 Drug Profile | 317 | 1 |
| Small Molecule for Atopic Dermatitis Drug Profile | 318 | 1 |
| Small Molecule to Modulate S1PR1 for Atopic Dermatitis Drug Profile | 319 | 1 |
| Small Molecules for Atopic Dermatitis Drug Profile | 320 | 1 |
| Small Molecules for Atopic Dermatitis Drug Profile | 321 | 1 |
| Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis Drug Profile | 322 | 1 |
| SP-14019 Drug Profile | 323 | 1 |
| SUN-0597 Drug Profile | 324 | 2 |
| SWT-01113 Drug Profile | 326 | 1 |
| SWT-05141 Drug Profile | 327 | 1 |
| Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders Drug Profile | 328 | 1 |
| tacrolimus Drug Profile | 329 | 1 |
| tezepelumab Drug Profile | 330 | 2 |
| tralokinumab Drug Profile | 332 | 2 |
| upadacitinib tartrate Drug Profile | 334 | 2 |
| ustekinumab Drug Profile | 336 | 6 |
| VTP-38543 Drug Profile | 342 | 1 |
| WBI-1001 Drug Profile | 343 | 2 |
| WOL-071007 Drug Profile | 345 | 1 |
| XmAb-7195 Drug Profile | 346 | 1 |
| YJC-10592 Drug Profile | 347 | 1 |
| Zafi-1 Drug Profile | 348 | 1 |
| ZPL-389 Drug Profile | 349 | 2 |
| ZPL-521 Drug Profile | 351 | 1 |
| Atopic Dermatitis Dormant Projects | 352 | 10 |
| Atopic Dermatitis Discontinued Products | 362 | 2 |
| Atopic Dermatitis Product Development Milestones | 364 | 10 |
| Featured News &Press Releases | 364 | 1 |
| Jul 13, 2016: Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis | 364 | 1 |
| Jul 06, 2016: AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial | 364 | 1 |
| Jul 05, 2016: AnGes Announces Top-Line Results for Japanese PhaseIII Clinical Trial of NF-B Decoy Oligonucleotide for Atopic Dermatitis | 365 | 1 |
| Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients | 365 | 1 |
| Jun 09, 2016: PuriCore successfully completes Pre-IND Meeting with the FDA on PR022 for Atopic Dermatitis | 366 | 1 |
| Jun 06, 2016: Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients | 367 | 1 |
| May 23, 2016: Medimetriks announces the results of a successful Phase 2 trial of MM36 in Atopic Dermatitis; Study results and design published in the Journal of the American Academy of Dermatology | 368 | 1 |
| May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389 | 369 | 1 |
| Apr 01, 2016: Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients | 369 | 2 |
| Mar 22, 2016: Anacor Pharmaceuticals Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis | 371 | 1 |
| Mar 10, 2016: AnaptysBio Announces First-In-Human Dosing of Anti-IL-33 Antibody | 371 | 1 |
| Mar 05, 2016: Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD | 372 | 1 |
| Feb 23, 2016: Anacor Pharmaceuticals Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase III Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology | 373 | 1 |
| Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases | 373 | 1 |
| Jan 08, 2016: Anacor Pharmaceuticals to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference | 373 | 1 |
| Appendix | 374 | 2 |
| Methodology | 374 | 1 |
| Coverage | 374 | 1 |
| Secondary Research | 374 | 1 |
| Primary Research | 374 | 1 |